Items where authors include "Sherborne, AL"
Article
Croft, J, Ellis, S, Sherborne, AL et al. (19 more authors) (2021) Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 35 (7). pp. 2043-2053. ISSN 0887-6924
Shah, V, Sherborne, AL, Johnson, DC et al. (16 more authors) (2020) Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia, 34. pp. 3091-3096. ISSN 0887-6924
Hoang, PH, Cornish, AJ, Sherborne, AL et al. (8 more authors) (2020) An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. Blood Cancer Journal, 10 (10). 101. ISSN 2044-5385
Jones, JR, Weinhold, N, Ashby, C et al. (19 more authors) (2019) Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, 104 (7). pp. 1440-1450. ISSN 0390-6078
Shah, V, Johnson, DC, Sherborne, AL et al. (19 more authors) (2018) Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood, 132 (23). pp. 2465-2469. ISSN 0006-4971
Shah, V, Sherborne, AL, Walker, BA et al. (19 more authors) (2017) Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1,905 trial patients. Leukemia, 32. pp. 102-110. ISSN 0887-6924
Chubb, D, Broderick, P, Dobbins, SE et al. (12 more authors) (2016) Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nature Communications, 7. 11883. ISSN 2041-1723
Proceedings Paper
Shah, V, Johnson, DC, Sherborne, AL et al. (18 more authors) (2018) Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San Diego, California, USA. American Society of Hematology , p. 2000.
Croft, J, Hall, A, Walker, K et al. (11 more authors) (2018) Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone. In: Blood. ASH 2018 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology , p. 4482.
Sherborne, AL, Shah, V, Ellis, S et al. (15 more authors) (2017) Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. In: Blood. 59th ASH Annual Meeting and Exposition, 09-12 Dec 2017, Atlanta, GA, USA. American Society of Hematology , p. 1767.